{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:38:35Z","timestamp":1789609115020,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40257-023-00785-5","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T12:02:01Z","timestamp":1684756921000},"page":"609-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and Safety of Abrocitinib in Patients with Severe and\/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial"],"prefix":"10.1007","volume":"24","author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuelle","family":"Viguier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin-Weller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Koulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"6","key":"785_CR1","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et\u00a0al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"key":"785_CR2","unstructured":"Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et\u00a0al. Euroguiderm guideline on atopic eczema. 2022. https:\/\/guidelines.edf.one\/uploads\/attachments\/cl9nz0zci00m9l7jn5ayr281q-0-atopic-eczema-gl-full-version-oct-2022.pdf. Accessed 28 Oct 2022."},{"issue":"12","key":"785_CR3","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et\u00a0al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"785_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et\u00a0al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"785_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et\u00a0al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"785_CR6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et\u00a0al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"key":"785_CR7","unstructured":"Pfizer Inc. CIBINQO (abrocitinib) tablets, for oral use [prescribing information]. 2022. Pfizer Inc.,: New York; 2022."},{"key":"785_CR8","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the Janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342.","journal-title":"Front Immunol"},{"issue":"6","key":"785_CR9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40257-020-00548-6","volume":"21","author":"S Ferreira","year":"2020","unstructured":"Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783\u201398.","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"785_CR10","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et\u00a0al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"10348","key":"785_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et\u00a0al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"9","key":"785_CR12","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et\u00a0al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"785_CR13","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/1203475418803628","volume":"22","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutan Med Surg. 2018;22(1):10S\u201316S.","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"785_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","volume":"84","author":"LFM Ari\u00ebns","year":"2021","unstructured":"Ari\u00ebns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et\u00a0al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dermatol. 2021;84(4):1000\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"785_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaip.2012.09.002","volume":"1","author":"PD Arkwright","year":"2013","unstructured":"Arkwright PD, Motala C, Subramanian H, Spergel J, Schneider LC, Wollenberg A. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013;1(2):142\u201351.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"785_CR16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s13555-021-00640-7","volume":"12","author":"JI Silverberg","year":"2022","unstructured":"Silverberg JI, Boguniewicz M, Waibel J, Weisman J, Strowd L, Sun L, et\u00a0al. Clinical tailoring of baricitinib 2 mg in atopic dermatitis: baseline body surface area and rapid onset of action identifies response at week 16. Dermatol Ther (Heidelb). 2022;12(1):137\u201348.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"785_CR17","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","volume":"87","author":"VY Shi","year":"2022","unstructured":"Shi VY, Bhutani T, Fonacier L, Deleuran M, Shumack S, Valdez H, et\u00a0al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022;87(2):351\u20138.","journal-title":"J Am Acad Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00785-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-023-00785-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-023-00785-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T16:32:21Z","timestamp":1687797141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-023-00785-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1007\/s40257-023-00785-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"11 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study and the Open Access fee were sponsored by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"ELS received grants from Pfizer Inc., Eli Lilly and Company, Kyowa Kirin, LEO Pharma, Merck, and Regeneron and personal fees from Pfizer Inc., Bausch Health (Valeant), Dermira, Eli Lilly and Company, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron, and Sanofi Genzyme. JIS served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron, and Sanofi; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron, and Sanofi Genzyme; and as a speaker for Regeneron and Sanofi-Genzyme. JPT is an advisor for Pfizer Inc., AbbVie, Almirall, Arena Pharmaceuticals, Aslan Pharmaceuticals, Coloplast, Eli Lilly and Company, LEO Pharma, OM Pharma, Regeneron, Sanofi-Genzyme, and Union Therapeutics; a speaker for Pfizer Inc., AbbVie, Almirall, Eli Lilly and Company, LEO Pharma, Regeneron, and Sanofi-Genzyme; and has received research grants from Pfizer Inc., Regeneron, and Sanofi-Genzyme. MV is an investigator, board member, and consultant for AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Medac, Novartis, and Sanofi. DT is a consultant, advisory board member, and investigator for Pfizer Inc., AbbVie, Almirall, Amgen, Beiersdorf, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Janssen-Cilag, LEO Pharma, Novartis, Regeneron, Samsung, Sandoz, Sanofi, Sun Pharma, and UCB Pharma. MdBW is a consultant, advisory board member, and\/or speaker for Pfizer, AbbVie, Almirall, Arena, Aslan, Eli Lilly and Company, Galderma, Janssen, LEO Pharma, Regeneron, and Sanofi Genzyme. SW has received institutional research grants from La Roche-Posay, LEO Pharma, and Sanofi Deutschland GmbH; has performed consultancies for Pfizer Inc., AbbVie, Eli Lilly and Company, Kymab, LEO Pharma, Novartis, Regeneron, and Sanofi Genzyme; has lectured at educational events sponsored by AbbVie, Galderma, LEO Pharma, Novartis, Regeneron, and Sanofi Genzyme; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. GC, MD, and PB are employees and shareholders of Pfizer Inc. CF is an employee and shareholder of Pfizer Ltd. CK is an employee of Pfizer Hellas S.A. MJC has been a clinical trial investigator for Pfizer Inc., Atopix, Galapagos, Hyphens, Johnson & Johnson, Kymab, LEO Pharma, L\u2019Oreal\/La Roche-Posay, Novartis, Regeneron, and Sanofi Genzyme and an advisory board member, consultant, and\/or invited lecturer for Pfizer Inc., AbbVie, Amlar, Astellas, Atopix, Boots, Dermavant, Galapagos, Galderma, Hyphens, Johnson & Johnson, Kymab, LEO Pharma, L\u2019Oreal\/La Roche-Posay, Menlo Therapeutics, Novartis, Oxagen, Procter & Gamble, Reckitt Benckiser, Regeneron, and Sanofi-Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All study documents and procedures were approved by the appropriate institutional review boards\/ethics committees at each study site. The studies were conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization Good Clinical Practice Guidelines. All local regulatory requirements were followed. This research was approved by institutional review boards or ethics committees at each study site. An internal review committee monitored the safety of patients throughout the studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See  for more information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and\/or Code Availability"}},{"value":"GC, PB, and CK contributed to the study concept and design. PB conducted the statistical analysis of the data. ELS, JIS, JPT, MV, DT MBW, SW, GC, MD, PB, CF, CK, and MJC interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}